Novan Investor Relations Material

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. It is engaged in developing nitric oxide-based therapeutics for the treatment of skin pathologies, including acne vulgaris and other inflammatory conditions such as psoriasis, atopic dermatitis, wound healing, endometriosis, hidradenitis suppurativa (HS) and eczema; and microbial infections in dermatology such as MRSA infections. The company's product candidate pipeline consists of two Phase 3 clinical stage candidates: M834 for HS and an acne treatment; as well as a Phase 2 clinical candidate for topical fungal infections.